Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives

Xiangyu Huo,Duoduo Hou,Haixia Wang,Bin He,Jieyu Fang,Yao Meng,Luyang Liu,Zhanyong Wei,Zhenya Wang,Feng-Wu Liu

DOI: https://doi.org/10.1016/j.ejmech.2021.113684

IF: 7.088

2021-11-01

European Journal of Medicinal Chemistry

Abstract:Respiratory syncytial virus (RSV) causes serious lower respiratory tract infections. Currently, the only clinical anti-RSV drug is ribavirin, but ribavirin has serious toxic side effect and can only be used by critically ill patients. A series of benzimidazole derivatives were synthesized starting from 1,4:3,6-dianhydro-d-fructose and a variety of o-phenylenediamines. Evaluation of their antiviral activity showed that compound a27 had the highest antiviral activity with a half maximal effective concentration (EC50) of 9.49 μM. Investigation of the antiviral mechanism of compound a27 indicated that it can inhibit the replication of RSV by inhibiting apoptosis and autophagy pathways. Retinoic acid-inducible gene (RIG)-I, TNF receptor associated factor (TRAF)-3, TANK binding kinase (TBK)-1, interferon regulatory factor (IRF)-3, nuclear factor Kappa-B (NF-κB), interferon (IFN)-β, Toll-like receptor (TLR)-3, interleukin (IL)-6 were suppressed at the cellular level. Mouse lung tissue was subjected to hematoxylin and eosin (HE) staining and immunohistochemistry, which showed that RSV antigen and M gene expression could be reduced by compound a27. Decreased expression of RIG-I, IRF-3, IFN-β, TLR-3, IL-6, interleukin (IL)-8, interleukin (IL)-10, inducible nitric oxide synthase (iNOS) and tumor necrosis factor (TNF)-α was also found in vivo.

chemistry, medicinal

What problem does this paper attempt to address?

The paper aims to address the following issues: 1. **Design and synthesis of novel benzimidazole derivatives**: Researchers designed and synthesized a series of novel oxazine-fused benzimidazole derivatives using 1,4:3,6-dianhydro-D-fructose (DAF) and various o-phenylenediamines as raw materials. 2. **Evaluation of anti-respiratory syncytial virus (RSV) activity**: The in vitro and in vivo anti-RSV activities of these compounds were evaluated, and compound a27 was found to have the highest antiviral activity, with a half-maximal effective concentration (EC50) of 9.49 μM. 3. **Exploration of antiviral mechanisms**: Further studies on the antiviral mechanism of compound a27 revealed that it can inhibit RSV replication by suppressing apoptosis and autophagy pathways. Additionally, a27 can inhibit the expression of multiple key signaling pathway proteins, such as RIG-I, TRAF-3, TBK-1, IRF-3, NF-κB, IFN-β, TLR-3, IL-6, etc. 4. **Validation of in vivo effects**: Mouse experiments confirmed that compound a27 can reduce the expression of RSV antigens and M gene in vivo, and alleviate lung injury and inflammatory response. Overall, this study aims to develop a new anti-RSV drug, particularly addressing the severe toxic side effects of the currently sole clinical anti-RSV drug, ribavirin. Compound a27 shows good anti-RSV activity and lower toxicity, indicating potential clinical application value.

Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives

Design, synthesis, and anti-respiratory syncytial virus potential of novel 3-(1,2,3-triazol-1-yl)furoxazine-fused benzimidazole derivatives

Luteolin Inhibits Respiratory Syncytial Virus Replication by Regulating the MiR-155/SOCS1/STAT1 Signaling Pathway

Structure-Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors

Andrographolide exerts anti-respiratory syncytial virus activity by up-regulating heme oxygenase-1 independent of interferon responses in human airway epithelial cells

Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex

Single-Stranded Oligonucleotide-Mediated Inhibition of Respiratory Syncytial Virus Infection

Discovery of gem-Dimethyl-hydroxymethylpyridine Derivatives as Potent Non-nucleoside RSV Polymerase Inhibitors

A new mechanism of respiratory syncytial virus entry inhibition by small-molecule to overcome K394R-associated resistance

Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus

Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein

Discovery of N-Containing (-)-Borneol Esters as Respiratory Syncytial Virus Fusion Inhibitors

Sonication-Assisted Self-Assembled Resveratrol Nanoparticles with Enhanced Antiviral and Anti-inflammatory Activity against Respiratory Syncytial Virus-Induced Pneumonia

Chlorobenzoxime inhibits respiratory syncytial virus infection in neonatal rats via up-regulation of IFN-γ in dendritic cells

Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents

JNJ-7184, a Respiratory Syncytial Virus inhibitor targeting the connector domain of the viral polymerase.

Orally active fusion inhibitor of respiratory syncytial virus.

Resveratrol inhibits respiratory syncytial virus replication by targeting heparan sulfate proteoglycan

Synthesis and biological evaluation of baloxavir marboxil analogs for the treatment of influenza A (H<sub>1</sub>N<sub>1</sub>) virus

Design, synthesis, antiviral activities of ferulic acid derivatives

Inhibition of Respiratory Syncytial Virus Infection by Small Non-Coding RNA Fragments